These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19003983)

  • 1. TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance.
    Wong N; Yeo W; Wong WL; Wong NL; Chan KY; Mo FK; Koh J; Chan SL; Chan AT; Lai PB; Ching AK; Tong JH; Ng HK; Johnson PJ; To KF
    Int J Cancer; 2009 Feb; 124(3):644-52. PubMed ID: 19003983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Karyotypic imbalances and differential gene expressions in the acquired doxorubicin resistance of hepatocellular carcinoma cells.
    Pang E; Hu Y; Chan KY; Lai PB; Squire JA; Macgregor PF; Beheshti B; Albert M; Leung TW; Wong N
    Lab Invest; 2005 May; 85(5):664-74. PubMed ID: 15765123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion.
    Chen L; Yuan YF; Li Y; Chan TH; Zheng BJ; Huang J; Guan XY
    Gut; 2011 Apr; 60(4):534-43. PubMed ID: 21068133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.
    Pierceall WE; Sprott KM; Heikkinen T; Heikkila P; Alaparthi L; Aittomaki K; Al-Adhami M; Villegas-Bergazzi V; Meyer JL; Kutok JL; Bartkova J; Bartek J; Nevanlinna H; Weaver DT; Blomqvist C
    Hum Pathol; 2012 Sep; 43(9):1363-75. PubMed ID: 22204715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpressed nuclear BAG-1 in human hepatocellular carcinoma is associated with poor prognosis and resistance to doxorubicin.
    Ni W; Chen B; Zhou G; Lu C; Xiao M; Guan C; Zhang Y; He S; Shen A; Ni R
    J Cell Biochem; 2013 Sep; 114(9):2120-30. PubMed ID: 23553841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
    Di Leo A; Desmedt C; Bartlett JM; Piette F; Ejlertsen B; Pritchard KI; Larsimont D; Poole C; Isola J; Earl H; Mouridsen H; O'Malley FP; Cardoso F; Tanner M; Munro A; Twelves CJ; Sotiriou C; Shepherd L; Cameron D; Piccart MJ; Buyse M;
    Lancet Oncol; 2011 Nov; 12(12):1134-42. PubMed ID: 21917518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TOP2A amplification and overexpression in hepatocellular carcinoma tissues.
    Panvichian R; Tantiwetrueangdet A; Angkathunyakul N; Leelaudomlipi S
    Biomed Res Int; 2015; 2015():381602. PubMed ID: 25695068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
    Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression analysis of TOP2A, MSH2 and MLH1 genes in MCF7 cells at different levels of etoposide resistance.
    Kaplan E; Gündüz U
    Biomed Pharmacother; 2012 Feb; 66(1):29-35. PubMed ID: 22285073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.
    Romero A; Martín M; Cheang MC; López García-Asenjo JA; Oliva B; He X; de la Hoya M; García Sáenz JÁ; Arroyo Fernández M; Díaz Rubio E; Perou CM; Caldés Llopis T
    Am J Pathol; 2011 Apr; 178(4):1453-60. PubMed ID: 21435434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive role of midtreatment changes in survivin, GSTP1, and topoisomerase 2α expressions for pathologic complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
    Eralp Y; Keskin S; Akışık E; Akışık E; İğci A; Müslümanoğlu M; Yılmaz S; Tunacı M; Çamlıca H; Tuzlalı S; Saip P; Dalay N; Özmen V; Topuz E
    Am J Clin Oncol; 2013 Jun; 36(3):215-23. PubMed ID: 22441341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
    Menendez JA; Vellon L; Lupu R
    Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer.
    Şahin S; Işık Gönül İ; Çakır A; Seçkin S; Uluoğlu Ö
    Int J Surg Pathol; 2016 Oct; 24(7):607-13. PubMed ID: 27284123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer.
    Park K; Han S; Gwak GH; Kim HJ; Kim J; Kim KM
    Breast Cancer Res Treat; 2006 Aug; 98(3):337-42. PubMed ID: 16502015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FBI-1 promotes cell proliferation and enhances resistance to chemotherapy of hepatocellular carcinoma in vitro and in vivo.
    Fang F; Yang L; Tao Y; Qin W
    Cancer; 2012 Jan; 118(1):134-46. PubMed ID: 21713761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Underpinning the repurposing of anthracyclines towards colorectal cancer: assessment of topoisomerase II alpha gene copy number alterations in colorectal cancer.
    Nygård SB; Christensen IJ; Smith DH; Nielsen SL; Jensen NF; Nielsen HJ; Vainer B; Brünner N
    Scand J Gastroenterol; 2013 Dec; 48(12):1436-43. PubMed ID: 24138107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients.
    Xu YC; Zhang FC; Li JJ; Dai JQ; Liu Q; Tang L; Ma Y; Xu Q; Lin XL; Fan HB; Wang HX
    Oncol Rep; 2015 Oct; 34(4):1883-94. PubMed ID: 26252353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial.
    O'Malley FP; Chia S; Tu D; Shepherd LE; Levine MN; Huntsman D; Bramwell VH; Andrulis IL; Pritchard KI
    Breast Cancer Res Treat; 2011 Jul; 128(2):401-9. PubMed ID: 21519837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics.
    Fasching PA; Weihbrecht S; Haeberle L; Gasparyan A; Villalobos IE; Ma Y; Ekici AB; Wachter DL; Hartmann A; Beckmann MW; Slamon DJ; Press MF
    Breast Cancer Res Treat; 2014 May; 145(1):193-203. PubMed ID: 24682655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients.
    Ejlertsen B; Jensen MB; Nielsen KV; Balslev E; Rasmussen BB; Willemoe GL; Hertel PB; Knoop AS; Mouridsen HT; Brünner N
    J Clin Oncol; 2010 Feb; 28(6):984-90. PubMed ID: 20038724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.